Type 1 diabetes (T1D) results from the progressive destruction of pancreatic β-cells in a
process mediated primarily by T lymphocytes. The T1D research community has made …

Over the past 15 years, SCT has emerged as a promising treatment option for patients with
severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of …

The adaptive immune repertoire plays a critical role in type 1 diabetes (T1D) pathogenesis.
However, efforts to characterize B cell and T cell receptor (TCR) profiles in T1D subjects …

Autoreactive CD8 T cells play a central role in the destruction of pancreatic islet β-cells that
leads to type 1 diabetes, yet the key features of this immune-mediated process remain …

Recent interest in testing whether the success of antigen-specific immunotherapy (ASIT) for
autoimmune diseases in mice can be translated to humans has highlighted the need for …

It is widely accepted that Type 1 diabetes is a complex disease. Genetic predisposition and
environmental factors favour the triggering of autoimmune responses against pancreatic β …

Abstract Purpose of Review The genetic susceptibility and dominant protection for type 1
diabetes (T1D) associated with human leukocyte antigen (HLA) haplotypes, along with …

As screening studies and preventive interventions for type 1 diabetes (T1D) advance rapidly,
the utility of islet autoantibodies (IAbs) in T1D prediction comes with challenges for early and …

Aims/hypothesis Validated biomarkers are needed to monitor the effects of immune
intervention in individuals with type 1 diabetes. Despite their importance, few options exist …

The current standard of care for type 1 diabetes patients is limited to treatment of the
symptoms of the disease, insulin insufficiency and its complications, not its cause. Given the …